Effect of herbal capsule, Viroherb, and herbal syrup, Fenugreek in treatment of COVID-19

Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200402046923N1

Enrollment

110

Registered

2020-04-09

Start date

2020-04-05

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Medications in national guideline+ Viroherb capsule 500 mg 2 caps every 12 h + Fenugreek syrup 10 cc every 6 h. Intervention 2: Control group: Medications in nation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Ability to understand and the willingness to sign a written informed consent document Aged 18 and more without sex restriction patients with mild to moderate form of COVID-19 according to national guideline not recieved any retroviral or immunostimulant medications in the past 3 months

Exclusion criteria

Exclusion criteria: pregnancy or lactation patients in whom COVID-19 in not confirmed Alcohol or drug addiction patients with hypertension patients with peptic ulcer patients with diabetes

Design outcomes

Primary

Measure	Time frame
Body temperature. Timepoint: At the beginning of the study and on day 6. Method of measurement: thermometer.;Adverse events. Timepoint: whole duration of study. Method of measurement: type and number of adverse event.;Cough. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Dyspnea. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Myalgia. Timepoint: At the beginning of the study and on day 6. Method of measurement: Visual Analogue Scale.	—

Measure

Time frame

Body temperature. Timepoint: At the beginning of the study and on day 6. Method of measurement: thermometer.;Adverse events. Timepoint: whole duration of study. Method of measurement: type and number of adverse event.;Cough. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Dyspnea. Timepoint: At the beginning of the study and on day 6. Method of measurement: clinical judgement of physician.;Myalgia. Timepoint: At the beginning of the study and on day 6. Method of measurement: Visual Analogue Scale.

—

Secondary

Measure	Time frame
Liver enzymes (ALT, AST). Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Creatinine. Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Blood Gas ABG. Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Duration of hospital and ICU stay. Timepoint: At the end of study. Method of measurement: day(s).;Complete blood count (CBC). Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Oxygen saturation. Timepoint: At the beginning of study and day 6. Method of measurement: Pulse oximetry.	—

Measure

Time frame

Liver enzymes (ALT, AST). Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Creatinine. Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Blood Gas ABG. Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Duration of hospital and ICU stay. Timepoint: At the end of study. Method of measurement: day(s).;Complete blood count (CBC). Timepoint: At the beginning of study and day 6. Method of measurement: Laboratory refferal.;Oxygen saturation. Timepoint: At the beginning of study and day 6. Method of measurement: Pulse oximetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoja Rahimi

Tehran University of Medical Sciences

rojarahimi@gmail.com+98 21 8899 0835

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026